Peregrine Pharmaceuticals PS-Targeting Immunotherapy Platform to Be Highlighted in Three Data Presentations at Keystone Sympo...
March 04 2014 - 04:00PM
Marketwired
Peregrine Pharmaceuticals PS-Targeting Immunotherapy Platform to Be
Highlighted in Three Data Presentations at Keystone Symposia
Conferences
Data to Highlight the Mechanism of Action and Therapeutic
Effects of the Company's PS-Targeting Antibodies in Oncology and
Anti-Viral Indications
TUSTIN, CA--(Marketwired - Mar 4, 2014) - Peregrine
Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today
announced the presentation of data from three preclinical studies
highlighting the immuno-oncology and anti-viral potential of
phosphatidylserine (PS)-targeting antibodies at two upcoming
Keystone Symposia to be held March 9-13, 2014. Bavituximab, the
company's lead immunotherapy candidate, is advancing in a Phase III
SUNRISE trial for the treatment of second-line non-small cell lung
cancer.
PRESENTATION DETAILS:
CONFERENCE: IMMUNE EVOLUTION IN CANCER Plenary Talk:
Phosphatidylserine-Targeting Antibodies Induce M1 Macrophage
Polarization, Promote Myeloid Derived Suppressor Cell
Differentiation and Boost Tumor-Specific Immunity Presenter:
Xianming Huang, Ph.D., Assistant Professor, Hamon Center for
Therapeutic Oncology, Pharmacology, Simmons Comprehensive Cancer
Center University of Texas Southwestern Medical Center, Dallas,
Texas Date: Wednesday, March 12, 2014 Time: 2:30 P.M. - 4:30 P.M.
Pacific Time Workshop: #3: Immune Suppressive Myeloid Cells
Location: MacDonald DEF Room, Fairmont Chateau Whistler, Whistler,
British Columbia, Canada
CONFERENCE: IMMUNE EVOLUTION IN CANCER Title: Phosphatidylserine
Targeting Antibodies Enhance the Activity of Immune Checkpoint
Inhibitors in Tumors Presenter: Bruce Freimark, Ph.D., Director of
Pre-Clinical Research Oncology, Peregrine Pharmaceuticals Poster:
Poster Session 1 - Poster 1029 Date: Monday, March 10, 2014
Viewing: 1:00 P.M. - 10:00 P.M. Pacific Time Presentation: 7:30
P.M. - 10:00 P.M. Pacific Time Location: Frontenac Ballroom and
Foyer - Fairmont Chateau Whistler, Whistler, British Columbia,
Canada
CONFERENCE: HIV PATHOGENESIS VIRUS VERSUS HOST Title:
Phosphatidylserine-Targeting Antibody Triggers B-Chemokine Release
from Monocytes by Cell-Cell Crosslinking and is a Potent Inhibitor
of HIV-1 In Vitro Presenter: Cyril Empig, Ph.D., Associate
Director, Pre-Clinical Research Infectious Disease, Peregrine
Pharmaceuticals Poster: Poster Session 3 - Poster 3020 Date:
Wednesday, March 12, 2014 Viewing: 1:00 P.M. - 10:00 P.M. Mountain
Time Presentation: 7:30 P.M. - 10:00 P.M. Mountain Time Location:
Mezzanine 2 - Fairmont Banff Springs, Alberta, Canada
About Bavituximab: A Targeted Immunotherapy Bavituximab is a
first-in-class phosphatidylserine (PS)-targeting monoclonal
antibody that represents a new approach to treating cancer. PS is a
highly immunosuppressive molecule usually located inside the
membrane of healthy cells, but "flips" and becomes exposed on the
outside of cells that line tumor blood vessels, creating a specific
target for anti-cancer treatments. PS-targeting antibodies target
and bind to PS and block this immunosuppressive signal, thereby
enabling the immune system to recognize and fight the tumor. These
data detailing the immune-stimulatory mechanism of action of
PS-targeting antibodies, such as the company's lead drug candidate
bavituximab, are the subject of a manuscript published in the
October 2013 issue of the American Association for Cancer Research
(AACR) peer-reviewed journal, Cancer Immunology Research.
Bavituximab is currently being evaluated in several solid tumor
indications, including non-small cell lung cancer, breast cancer,
liver cancer and rectal cancer with a trial in advanced melanoma
anticipated to initiate in the near future.
About Keystone Symposia Keystone Symposia serve as a catalyst
for the advancement of biomedical and life sciences by connecting
scientists within and across disciplines at conferences and
workshops held at venues that create an environment conducive to
information exchange, generation of new ideas and acceleration of
applications that benefit society.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company
with a pipeline of novel drug candidates in clinical trials focused
on the treatment and diagnosis of cancer. The company is pursuing
multiple clinical programs in cancer with its lead immunotherapy
candidate bavituximab while seeking a partner to further advance
its novel brain cancer agent Cotara®. Peregrine also has in-house
cGMP manufacturing capabilities through its wholly-owned subsidiary
Avid Bioservices, Inc. (www.avidbio.com), which provides
development and biomanufacturing services for both Peregrine and
third-party customers. Additional information about Peregrine can
be found at www.peregrineinc.com.
Contact: Christopher Keenan or Jay Carlson Peregrine
Pharmaceuticals (800) 987-8256 info@peregrineinc.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2023 to Mar 2024